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Abstract
Background: Human papillomavirus (HPV) vaccines were designed to prevent cervical cancer in women and their
provision remains a major public health need. However, HPV is also a major cause of non-cervical anogenital and
oropharyngeal cancers and the potential benefit of vaccination likely extends beyond cervical cancer.
Methods: A systematic literature search of PubMed (1995–2014) identified publications assessing the incidence,
persistence, and clearance of non-cervical anogenital/oral HPV infections. Comparability with cervical HPV was
assessed by identifying articles assessing the same or similar populations.
Results: Available data suggest high incidence rates of non-cervical HPV infection in men and women, with HPV-16
predominating in all sites. The incidence of high risk HPV per 100 person-years ranged from 11.4 to 72.9 for penile
infections, 6.7–47.9 at other male genital sites, and 4.4–36.7 and 5.3–23.4 for anal infections in men and women,
respectively. The incidence per 100 person-years of oral infection with any HPV type ranged from 5.7 to 6.7 in
men and 6.8–39.6 in women. Within the limitations of the data, there was a general pattern of higher incidence
and clearance of non-cervical genital HPV infections, compared to cervical infections. HIV status, circumcision,
number of sex partners and partner HPV status significantly influenced high-risk HPV incidence/clearance at male
anogenital sites. Few studies assessed risk factors for oral HPV.
Conclusions: Parallels appear to exist between the epidemiology of cervical and non-cervical HPV infections in
terms of incidence, HPV-type distribution, and risk factors for infection. Available data suggest that non-cervical
genital HPV infections may occur more frequently, with higher clearance rates, than cervical infections. More
extensive studies could provide useful information for estimating vaccine impact, the wider cost-benefit of HPV
vaccination, and guiding vaccination policy.
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Background
Cervical cancer is the fourth most common cancer
affecting women worldwide, with an estimated 528,000
new cases and 266,000 related deaths in 2012 [1]. Cervical
cancer develops following persistent infection with onco-
genic (or high risk) types of the human papillomavirus
(HPV), that includes types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 [2]. Approximately 70 % of cervical cancers
are caused by HPV types 16 and 18, which along with
several other high risk HPV types (HR-HPV), can be
prevented by vaccination. However, the cancer-causing
effects of HPV are not limited to the cervix; an estimated
50 % of penile, 88 % of anal, 43 % of vulvar, 70 % of vaginal,
and 13–56 % of oropharyngeal cancers are attributable to
HPV, primarily HPV-16 typically followed by HPV-18 [3,
4]. Sharply increasing trends in HPV-related oropharyngeal
cancers have been observed in some countries [5]. The inci-
dence of cervical cancer is far higher than that of non-
genital or oropharyngeal cancers, and the provision of HPV
vaccines to prevent cervical cancer remains a public health
priority. However, together non-cervical and oropharyngeal
cancers represented approximately 80,000 new HPV-
related cancer cases worldwide in 2008, also signifying an
important public health burden [6].
Available evidence from clinical trials indicates that
current HPV vaccines can prevent vulval and vaginal and
anal HPV infections, anogenital pre-cancers, and oral
HPV infections [7] in women, and oral and anogenital
infections and pre-cancer in men [7–14]. However, com-
pared to vaccine efficacy/effectiveness data for cervical
HPV infections and high-grade lesions, similar data for
non-cervical HPV infections and lesions are scant. More-
over, our ability to measure the population level impact of
HPV vaccination on non-cervical cancers is severely
limited by a lack of systematic screening for non-cervical
infections and pre-cancers, the relative rarity of these can-
cers, and for some, the absence of precursor lesions amen-
able to screening. The need to build ways of collecting
such data nonetheless remains important to understand
the full value of HPV vaccination, including cost-benefit,
so that proper guidance can be given to vaccination policy.
To this end, we conducted a systematic literature review
to investigate the natural history of non-cervical HPV
infections, and to identify parallels between the epidemi-
ology of these infections and that of cervical infection.
These data can inform on the design and scope of future
studies of HPV vaccine effectiveness, aid in the interpret-
ation of surveillance data, and point to knowledge gaps
where further investigations may be warranted.
Methods
Objectives
The study objectives were to conduct a systematic re-
view of the literature to describe the incidence, clearance
and persistence of non-cervical HPV infections, includ-
ing comparisons to cervical infections for which data
were available for the same/or similar study population.
We also examined risk factors for incident and persist-
ent non-cervical HPV infections.
Search strategy and selection criteria
A systematic review of the literature in PubMed used three
search strings (Supplementary material) to identify non-
cervical anogenital and oral HPV infections and was
limited to studies published in English between 01 January
1995 and 12 July 2014. We used specific searches to obtain
articles on cervical HPV infections reporting comparable
estimates of incidence, clearance, or persistence in the
same or similar populations and using comparable HPV
testing methods as in the articles on non-cervical HPV
infections. Articles were included if they contained infor-
mation on incidence, persistence, clearance or duration of
non-cervical HPV infections, risk factors for non-cervical
HPV infections or risk groups for incidence of non-
cervical infections. Articles were excluded if they reported
diagnostic test research, if they were case studies, letters to
the editor, editorials or comments, literature reviews, or
meta-analyses presenting no original data. Articles were
also excluded if no information was listed in the inclusion
criteria, or if they reported data based on testing of self-
collected vaginal samples only. PRISMA guidelines were
followed for the report. Independent review in duplicate
was undertaken for 30 % of screened titles and abstracts
and for 10 % of full text articles. Article selection, data
extraction, assessment of risk factors and quality control
procedures are provided in Additional file 1.
During the search for cervical cohorts, studies were
found which used self-collected vaginal samples but in
which the samples were referred to as ‘cervical’ swabs.
These studies were not identified with the original non-
cervical search string that did not include the term ‘cer-
vical’. We did not include studies when vaginal samples had
been self-collected, because the original search may have
missed studies that assessed self-collected vaginal samples,
and because we could not be certain that they represented
vaginal-only infections. For similar reasons cervical samples
collected using cervical vaginal lavage in D’Souza et al. [15]
were also excluded because we could not be certain that
they represented cervical-only infections.
For ease of comparability, incidence, clearance and
persistence rates were recalculated, if not provided, per
100 person-years, and all estimates of median (or mean
if median not reported) time-to-clearance (or duration
of infection) were calculated in terms of months. For
example, conversion from 1000 person-months to 100
person-years values was done by multiplying by 12 and
dividing by 10. All estimates of median time-to-clearance
were calculated in terms of months (dividing days by 30.5).
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When confidence intervals (CI) were not already provided
and there was sufficient data, we used the exact method to
calculate 95 % CI for proportions.
Ethics approval was not required for this study.
Definitions
The definition of HR-HPV was study specific. The HR-
HPV types applicable to individual studies are provided
in Additional file 2: Table S1.
Clearance, incidence, persistence, and duration of
infection were defined broadly to capture the most stud-
ies: For individual HPV types (e.g., HPV-16), incidence
was defined as at least one positive test for that HPV type
following at least one negative test for that type. Clearance
of infection was defined as a negative test for the individ-
ual HPV type following a positive test for that type.
Type-specific incidence of any HPV or HR-HPV was
defined as a positive test for at least one HPV type or HR-
HPV type not detected at baseline or other previous visit.
For non-type-specific incidence, subjects were required to
have tested negative for any HPV DNA or any HR-HPV
DNA at baseline. We considered this to be non-type-
specific incidence even if the HPV type(s) associated with
the incident infection was known. In addition, for studies
conducting multiple follow-up visits, incidence rates could
be calculated by: 1) censoring subjects at the time of the
first positive test (first acquired incidence); or 2) consider-
ing subjects to be at risk throughout the follow-up period
and counting each visit where at least one new type was
detected as an event (total acquired incidence).
Type-specific clearance of any HPV or HR-HPV was
defined as a negative test for all HPV types or HR-HPV
types detected at baseline (type-specific clearance of
prevalent infection) or for all newly detected during
follow-up (type-specific clearance of incident infection).
Non-type-specific clearance was defined as at least one
negative test for any HPV DNA or any HR-HPV DNA
following a positive test for any HPV DNA or HR-HPV
DNA at baseline or during follow-up.
Persistence was defined as at least two sequentially
positive tests for at least one specific HPV type or HR-
HPV type at least three months apart. Definitions for
type-specific and non-type specific duration of infection
followed those for clearance of infection.
For estimates related to any HPV and HR-HPV, calcu-
lations were required to be based on the total number of




We identified 38 articles from 25 unique study cohorts with
relevant data on non-cervical anogenital or oral HPV infec-
tions (Table 1). A further 6 articles were identified that
assessed cervical HPV infection in the same/similar popula-
tions. HPV-testing methods are summarised in Additional
file 2: Table S1. Three articles were excluded due to unclear
methods. Articles excluded due to improper testing methods
or sample type were included under ‘no relevant data’.
Median follow-up times varied between 6.7 and
84.5 months, with all but 8 studies conducting at least two
follow-up visits at intervals ranging between 2 and
12 months. Among the 31 studies reporting data on
incidence of any HPV or any HR-HPV, 10 (32 %) used
type-specific definitions which counted any newly
detected type as an incident infection and 17 (55 %) used
non-type-specific definitions that required subjects to be
negative for any HPV or any HR-HPV at baseline; an
additional 4 studies reported data on incidence of individ-
ual HPV types only. A total of 31 studies were known to
have multiple follow-up visits. Among the 31, 20 assessed
incidence of any HPV or HR-HPV: 13/20 (65 %) estimated
incidence based on time to the first acquired infection; 3/
20 (15 %) considered each new infection as an event; for
2/20 it was unclear (10 %); 1/20 (5 %) used both methods;
and 1/20 (5 %) did not conduct any survival analysis.
Among the 29 studies reporting data on HPV clearance,
type-specific definitions were used more consistently, with
only 5 (17 %) using non-type-specific definitions. Three
studies (10 %) required at least two consecutive negative
test results to define an infection as having cleared.
Penile HPV infections
Incidence
In studies conducted in Africa, HR-HPV incidence was
higher in human immunodeficiency virus positive (HIV +
ve) men (42.0–72.9/100 person-years) than HIV negative
(HIV-ve) men (19.7–32.9/100 person-years) (Table 2).
Studies in Spain reported higher HPV incidence in HIV +
ve men who have sex with men (MSM) than in men who
have sex with women (MSW) (11.6 versus 5.1/100 person-
years), but similar incidences of HPV-16 and HPV-18 infec-
tion. Genotype-specific incidence was highest for HPV-16
in at least one study subgroup in 7/9 studies (HIV + ve,
HIV-ve, circumcised, uncircumcised and MSW) [8, 16–21].
In three articles that reported age-specific incidence of
HPV infection the highest incidence was reported in the
youngest age group studied (<30 or 15–24 year olds)
[18, 19, 22].
Clearance and persistence
The rate of clearance of incident HR-HPV infection was
123.9/100 person-years (Table 2), with HPV-33 clearing
most rapidly and HPV-58 least rapidly [22].
The clearance rate of prevalent penile infections
ranged between 23.6 and 114.1/100 person-years for any
HPV [19, 20, 23]. Clearance of HR-HPV was 114.7/100
person-years in HIV + ve men and 170.2/100 person-
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Table 1 Summary of 38 articles included in the review
Author, study
location (ref)
Study year Population Age Number Follow-up period







Tobian, Uganda [19] 2003–2007 HIV + ve/-ve men 15–49 999 2 years (6, 12, 24 m) Mean 14.4 m Penile Inc (TS, total)
Clr (TS)
Kjaer, Denmark [63] 2000–2003 Military servicemen 18–19 374 6 m (6 m) Range 5.4–7.8 m Penile Inc (NTS)
Backes, Kenya [17] 2002–2005 Uncircumcised men 17–24 966 1 year (6, 12 m) Median 12.1 m Penile Inc (NTS, first)
Mbulawa, South
Africa [22]
Not reported HIV + ve/-ve men 19–67 486 2 years (6, 12, 18, 24 m) - Penile Inc (TS, first)
Clr (TS)a




Not reported MSW, sexually active
without clinical HPV




Gray, Uganda [18] 2003–2006 HIV-ve married men 15–49 840 24 m (6, 12, 24 m) - Penile Inc
Clr
Serwadda, Uganda [16] 2003–2007 HIV + ve men 15–49 210 24 m (24 m) - Penile Inc (TS)
Clr
Grabowski, Uganda [24] 2003–2007 HIV + ve/-ve men 15–49 936 24 m (6, 12, 24 m) - Penile Pers (TS)
Giuliano, Brazil,
Mexico, USA [53]
2005–2009 HIV-ve men 18–70 1159 4 years (every 6 m) Median 27.5 m Penile Inc (NTS, first)
Clr (TS)








2005–2009 Men 18–70 MSM:156
MSW:954













18–85 431 5 years (every 4 m) Mean 16 m Anal Clr (TS)
Moscicki, USA [40] 1990- > 2004 Sexually active
women
13–21 75 3–9.5 years (every 4 m) Mean 84.5 m Anal Clr (TS, 2+ neg)
Mullins, USA [37] 1996–2001 HIV + ve and
HIV-ve at risk
12–18 496 6 years (annual) Mean 22.4 m Anal Inc (NTS, first)
Glick, USA [33] 2009–2010 MSM 16–30 94 1 year (every 6 m) - Anal Inc (NTS, unclear)
Clr (TS)













Table 1 Summary of 38 articles included in the review (Continued)












Clr (TS, 2+ neg)
Giuliano,
Arizona USA [25]
















Partridge, USA [29] 2003–2006 MSW university
students



















Clr (TS, 2+ neg)
Winer, USA [43] 1990–2000 Female university
students
18–20 444 10 year (every 4 m) Mean 41.2 m Vulvovaginal Inc (NTS, first)
Edelstein, USA [45] 2008–2010 Male university students Median 20 212 1.5 years (every 4 m) Median 10.7 m Oral (rinse/OP swab) Inc (NTS, first)
Kero, Finland [48] Not reported Male partners of
pregnant women
19–46 131 7 years (2, 6, 12, 24,
36 m & 7 years)
Mean at visit 1:
1.8 m, visit 2: 5.9 m,
visit 3: 12.1 m,
visit 4: 24.7 m,
visit 5: 36.8 m,
visit 6: 77.0 m
Oral (scraping) Inc












Kero, Finland [46] Not reported Males partners of
pregnant women
20–52 129 men 7 years (2, 6, 12, 24, 36,
7 years)
Mean in 74
HPV + ve 43.8 m














Table 1 Summary of 38 articles included in the review (Continued)
Louvanto,
Finland [51]




Mean 25.2–26.4 43 cases
52 controls
6 years (possibly annual) Mean 65.2 m (cases)
38.4 m (controls)
Oral (scraping) Clr(TS)







2 years (2, 6, 12, 24 m) Mean 26.9 m (women)
25.9 m (men)
Oral (scraping) Inc (NTS, first)
Clr (NTS)
Pickard, USA [49] 2009–2010 University students 18–30 1000 3 m (3 m) - Oral (rinse) Inc (TS)
Clr (TS)
Pers (TS)
D’Souza, USA [15] 2004–2005 HIV + ve and high-risk
HIV-ve adult women
Not reported 199 6 m (6 m) - Oral (rinse) Inc (TS)
Clr (NTS)
Kurose, Japan [52] 2000–2002 Healthy volunteers 3–85 662 2.5 years (2.5 years) - Oral (scraping) Clr (TS)
Pers (TS)
Darwich, Spain [47] 2005–2009 HIV + ve men Median 41 733 5 years (annual) Median 24 m Oral (scraping/rinse) Clr (TS)
Kreimer, Brazil,
Mexico, USA [44]
2007–2009 HIV-ve men 18–70 1626 4 years (every 6 m) Median 12.7 m Oral (rinse) Inc (NTS, first)
Clr (TS)
Abbreviations: IQR interquartile range, MSM men who have sex with men, MSW men who have sex with women, Inc incidence, Clr clearance, Pers persistence, Circ circumcised, UnC uncircumcised, OP oropharyngeal
aIf HPV types present-negative-present in sequential visits then negative result was considered false
bIn calculation of incidence of individual HPV types, subjects were required to be negative for any HPV DNA at baseline at not just negative for that type
cDefinitions for Any or Any HR-HPV infections: TS type specific. For incidence, defined as a positive test for at least one HPV type or HR type not detected at baseline (or other previous visit). For clearance, defined as a
negative test for all HPV types or HR-HPV types detected at baseline or newly detected during follow-up. NTS non-type-specific. For incidence, defined as testing negative for any HPV DNA or any HR HPV DNA at baseline.
For clearance, defined as at least one negative test for any HPV DNA or any HR-HPV DNA following a positive test at baseline or during follow-up. 2+ neg 2+ negative test results required to define an infection as having





















Any HPV HR 16 18
Penile
Tobian [19] HIV-ve, 15–49
HIV + ve,15–49
























Gray [18] HIV-ve I, 15–49
HIV-ve C, 15–49




















Serwadda [16] HIV + ve I, 15–49
HIV + ve C, 15–49




















Kjaer [63] Military, 18–29 % at 6 m 13.8 (NTS)
(8.6–19.0)
- - - - - - - - -

























- - - - - -
Mbulawa [22] All, 18–66
HIV-ve, 18–66
HIV + ve 18–66






























HIV + ve MSM,
20- > 69
HIV + ve MSW,
20- > 69
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% at 12 m























































































% at 7 years 32.3 (NTS)
(16.7–51.4)
- - - Prevalent % at 7 years 88.9 % (TS)
(51.8–99.7)
- - -
Abbreviations: MSM men who have sex with men, MSW men who have sex with women, py person-years, UnC Uncircumcised, Circ Circumcised, m months, I Intervention (immediate circumcision), C Control
(circumcision delayed for 24 months), TS type-specific incidence defined as at least one positive test for any HPV type or HR-HPV type not detected at baseline, NTS non-type-specific incidence defined as at
least one positive test for any HPV type or HR-HPV type among those negative for any HPV DNA or any HR-HPV DNA at baseline













years in HIV-ve men [19]. HPV types tending to clear
the least rapidly were HPV-52 and 16 in circumcised men,
52 and 58 in uncircumcised men over a 2-year period [18],
52 and 16 in HIV + ve MSM and 18 and 51 in HIV + ve
MSW up to 5 years of follow-up [20], depending on study
and population. Age-specific clearance rates were highest in
men aged >30 years in two studies [19, 22].
Time-to-clearance was 12.2 months for HPV-16 and
6.3 months for HPV-18 in HIV-ve men, versus 27.8–
35.3 months for HPV-16 and 18 in HIV + ve men (Fig. 1).
HR-HPV persisted in 31 % of HIV-ve men and 43 % of
HIV + ve men at 6 months, and in 25 %/28 %, respectively,
at 12 months [24] (Table 3). Persistence of HR-HPV at
12 months was associated with higher HPV viral load at
baseline in HIV + ve men [24].
Cervical infections in comparable populations
In South Africa, incidence and clearance of penile and
cervical infections was assessed among 468 male–female
couples aged 18–67 years (Table 4) [22]. Incidence and
Fig. 1 Median* Time to clearance (months, 95 % CIs) of HPV from non-cervical sites in men and women. Footnote: *mean reported for
[20, 46, 47, 51]. TS type-specific incidence defined as at least one positive test for any HPV type or HR-HPV type not detected at baseline;
NTS non-type-specific incidence defined as at least one positive test for any HPV type or HR-HPV type among those negative for any HPV
DNA or any HR-HPV DNA at baseline
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clearance rates were significantly higher among men
compared with women (incidence of any HPV 66.8 ver-
sus 40.7/100 person-years; clearance of any HPV 114.1
versus 80.3/100 person-years). In regression analyses
adjusting for HPV type, incidence rates remained higher
in men when stratified by age-group and HIV status;
clearance rates remained higher in men when stratified
by age-group and among HIV + ve individuals (Table 4).
HIV status was the only significant predictor of clear-
ance in men and women, whereas in multivariate ana-
lyses, incidence was significantly predicted by HIV status
and partner infection with same HPV type in men and
women, and age at first sex and hormonal contraceptive
use in women only.
Male genital HPV infections
Male genital sites included samples from the scrotum,
coronal sulcus or combined samples of both penile and
non-penile sites (Table 2).
Incidence
Incidence of any HPV ranged from 14.8 to 50.51/100
person-years in adult men and military men [25–28]. In-
cidence in university students (median follow-up of
12.9 months) was 62.4 % [29]. Incidence in male part-
ners of pregnant women was 32.3 % over 7 years after
the initial assessment [30]. HPV-16 was the most fre-
quently identified type in all studies, followed by 52 and
58 [25–27, 29], or 51 and 59 [28].
Two studies reported on age-specific incidences of
male genital infections, of which one was restricted to
18 or 19 year olds [29]. In an adult population the high-
est incidence was observed in the oldest age group stud-
ied (41–44 years) for any HPV infection (55.6/100
person-years), but the highest incidence of HR-HPV was
in 26–30 year-olds (33.1/100 person-years) [31].
Clearance and persistence
Median time-to-clearance of any HPV male genital
infection was 3.5–7.1 months (Fig. 1). Time-to-clearance
of HPV-16 was 7.1–11.1 months, and 5.4–6.5 months
for HPV-18.
The median duration of incident male genital HPV
infections ranged between 5.1 and 7.1 months [25, 26,
28]. The duration of HPV-16 and/or 18 infection ranged
between 5.4 and 11.1 months [25, 26, 28]. In the United
States (US), HR-HPV genital infections persisted in 42 %
of men at 6 months, 19 % at 12 months and had cleared
in all men at 18 months [25] (Table 2).
Cervical infections in comparable populations
Incidence of male genital and cervical infections was
assessed in two similar but separate cohorts of men and
women from Arizona (Table 4) [25, 32]. Incidence calcu-
lated based on the first acquired infection with any HPV
was similar in men and women (35.3/100 person-years
[95 %CI 27.4–44.9] versus 35.3/100 person-years [95 %
CI 24.7–48.8]), but the cumulative incidence of infection
by 12 months was substantially higher in men than in
women (41 % versus 29 % [95 % CI 22–36] for any HPV;
32 % versus 19 % [95 % CI 13–25) for HR-HPV). Median
time-to-clearance for penile compared with cervical
Table 3 Type-specific persistence of HPV infections






























































Prevalent 30 50 (9–93) 0 (0–98) 0 (0–98) -
Abbreviations: MSM men who have sex with men, MSW men who have sex with women
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Table 4 Comparison of non-cervical HPV infections and cervical HPV infections in same or similar study populations
Ref, site Population, age (years) Incidence (95 % CI) Clearance (95 % CI)
Unit Any HR 16 18 Inf. type Unit Any HR 16 18
Darwich; Spain;
Penile [20]
HIV + ve MSM,
20- > 69








HIV + ve MSW,
20- > 69
Per 100py - - 1.4
(0.4–3.7)






HIV + ve women,
20–64








Comment: Study period 1999–2003 for women v. 2005–2009 for men
Mbulawa; South Africa;
Penile [22]





















HIV + ve/-ve Women in a
relationship, 18–66
















Comment: Incidence and clearance significantly higher in men v. women. In type- adjusted analyses, incidence remained higher in men by age group and HIV status; clearance remained higher in
men by age group and HIV + ve (96.4 versus 66.0/100 person-years), but not HIV-ve (128.1 versus 132.1/100 person-years)
Giuliano; USA (Arizona);
Male genital [25]


























- - - - - -
Comment: Study period 2003–2005 for men v. 1996–1999 for women; follow-up at 6, 12, and 24 months for men v. 4 and 10 months for women. Med time to clearance anal v. cervical: 5.9 m











































Comment: 431 of 972 women in cervical analysis as per availability of anal sample, complete questionnaire data, and valid HPV testing results. Med time to clearance anal v. cervical: 7.8 m (5.2–9.2)





- - - - - Prev % at 12 m - 29.7




















Table 4 Comparison of non-cervical HPV infections and cervical HPV infections in same or similar study populations (Continued)
Comment: Anal and cervical analyses conducted on two partially overlapping cohorts of 75 and 531 women, respectively. Clearance defined as time to first of 2 consecutive negative results; data for
any HPV not presented as cervical assay detected only 5 of 19 low-risk types detected by anal infection assay. HPV types 68, 69, 73, and 82 defined as HR types in analysis of anal but not cervical
















- - - - - - - - -





% at 7 years 32.3 (NTS)
(16.7–51.4)





Pregnant women, 19–46 % at 7 years 14.0 (NTS)
(5.3–27.9)





Pregnant women, 19–46 % at 7 years 16.7 (NTS)
(6.4–32.8)
- - - Prev % at 7 years 70 (TS)
(34.8–93.3)
- - -
Comment: Analysis based on only 46 men and 46 women returning for follow-up at 84 months. At year 7 the same infecting HPV genotype was detected in 11 % (95 % CI 0.3–48.2) and 30 %
(6.7–65.2) of mean and women, respectively. HPV status during interval visits was not taken into account.
Note: For male versus female comparison only date for penile/male genital infections versus cervical infections are presented
Abbreviations: m months, − data not provided, TS type-specific incidence defined as at least one positive test for any HPV type or HR-HPV type not detected at baseline, NTS non-type-specific incidence defined as at













infections was 5.9 months (95 % CI 5.7–6.1) versus ap-
proximately 9 months for any HPV, and 5.8 months (95 %
CI 5.5–6.1) versus 8.5 months for HR-HPV. In Finland,
where male genital and cervical infection data were col-
lected at baseline and 7 years later among 46 pregnant
women and their male partners, incidence and clearance
of any HPV was also higher among men versus women:
32.3 % (95 % CI 16.7–51.4) versus 16.7 % (95 % CI 6.4–
32.8) and 90 % (95 % CI 55.5–99.7) versus 70.0 % (95 % CI
34.8–93.3) (Table 4). Among men and women with genital
HPV infections at baseline, the same infecting HPV geno-
type was present at the 7-year follow-up in 11 % (95 % CI
0.3–48.2) and 30 % (6.7–65.2), respectively [30].
Anal HPV infections
Ten articles reported on anal HPV infections: seven
reported infections in men and four in women (Table 5).
Incidence in men
The incidence of anal HPV infection was higher in HIV +
ve men (gender of partner not specified) and HIV-ve
MSM (range 21.3–46.2/100 person-years), than in HIV +
ve MSW (7.9/100 person-years) and MSW (HIV status
not specified, 9.7/100 person-years). Among MSM, HPV-
16 and 18 were among the HPV types with the highest in-
cidence, although depending on the study, the incidences
of HPV-51, 52 or 59 were similar or higher [33–35].
Incidence in women
In women, anal HPV incidence ranged from 14–56.3/100
person-years. HPV-16 and 52 were the most frequently in-
fecting types [36]. The incidence of any and HR anal HPV
infection in 12–18 year olds was higher in men than
women (HIV-ve and HIV + ve), although the 95%CIs over-
lapped (Table 5) [37]. By contrast, in another study in
women [36] the incidence (per 100 person-years) of any
anal HPV infection was higher (56.3) than in all studies
reported in male populations (range 7.9–46.2) (Table 5).
In this study the incidence (per 100 person-years) of HR-
HPV infection in women (23.4) was higher than that
reported in MSW (4.4) and within the range observed in
HIV + ve men or MSM (13.3–36.7).
A regression analysis conducted in a US study of sexu-
ally active women noted a statistically significant inverse
relationship between acquisition of a new HR-HPV anal
infection and age; with a 57 % (95 % CI 19–77) lower
risk of acquisition among older women (≥45 years of age
at baseline) than among younger women (<25 years at
baseline) [36].
Clearance and persistence in men and women
Seven articles reported on the clearance rate of anal infec-
tions, of which five were in men who were HIV + ve and/
or MSM, and two were in women (Table 5). The clearance
rate of prevalent anal HPV infections in men varied
between 14.6 and 66.7/100 person-years for specific HPV
types. Amongst HR-HPV, the clearance rate was lowest
for HPV-16 in 5/6 populations [20, 33, 35, 38]. For HPV-
16 and 18 the time-to-clearance ranged between 30 and
39.5 months (Fig. 1).
In women, the clearance rate of incident anal HPV
infections was 89.3/100 person-years, with a median time-
to-clearance of 7.8 months [39] (Fig. 1). In another study,
56.5 % of women cleared any HR-HPV infection by year 3
[40]. In the single study that reported clearance of preva-
lent infections, HPV clearance in women appeared to be
within the range reported in studies in men (Table 5).
HR-HPV anal infections persisted at 6 months in
51.0 % of MSW and in 24.2 % of MSM who were HR-
HPV positive at baseline [35] (Table 3).
Cervical infections in comparable populations
In Hawaii, anal and cervical samples were collected in sexu-
ally active women aged 18–85 years every 4 months for an
average of approximately 1.3 years [36, 39, 41]. Incidence
(per 100 person-years) of anal versus cervical infections was
more than three-fold higher for any HPV (56.3 [95 % CI
48.5–65.0] versus 15.6 [95 % CI 12.9–18.7]) and more than
two-fold higher for HR-HPV (23.4 [95 % CI 19.2–28.3] ver-
sus 11.1 [95 % CI 9.0–13.6]); differences were similar for
HPV-16 and 18 infections but not statistically significant
(Table 4). Baseline cervical HPV status was not a significant
risk factor for incidence of anal HPV infection. In contrast,
clearance (per 100 person-years) did not significantly differ
between anal versus cervical infections with either any
HPV (89.3 [95 % CI 67.8–115.4] versus 85.1 [95 % CI 64.2–
110.4], respectively) or with HR-HPV (109.9 [95 % CI 83.3–
142.4] versus 92.0 [95 % CI 67.8–122.0], respectively).
In two partially overlapping cohorts of sexually active
teenager and young adults in the US, clearance by
12 months was also similar for anal versus cervical infec-
tions (29.7 % [95 % CI 19.0–41.7] and approximately
35 %, respectively) [40, 42]. In the Hawaii cohort, there
was some indication of higher clearance of anal than
cervical HPV-16 and 18 infections, with more than two-
fold differences in the median duration of infection (4.3
versus 9.8 months, and 6.9 versus 14 months, respect-
ively), but CIs overlapped substantially (data not shown)
[36, 39, 41].
Vaginal HPV infections
We identified one study of vulvovaginal HPV infections
that employed physician-collected swabs [43]. The
incidence rate for vulvovaginal HPV infections among
university students was 16.0 per 100 person-years (95 %
CI 13.7–18.6) compared with 12.7 per 100 person-years
(95 % CI 10.8–14.9) for cervical infections (Table 4). No
information on clearance or persistence was available.
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Table 5 Incidence and clearance of anal HPV infections
Author (ref) Population, age (yrs) Incidence (per 100py) Clearance

















































Videla [23] HIV + ve MSM,
20- > 69












Darwich [20] HIV + ve MSM,
20- > 69


















Mullins [37] HIV-ve, 12–18
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Moscicki [40] Sexually active
women, 13–21






Mullins [37] HIV-ve women,
12–18











- - - - - - - -
Abbreviations: MSM men who have sex with men, MSW men who have sex with women, py person-years, TS type-specific incidence defined as at least one positive test for any HPV type or HR-HPV type not detected














Eleven articles (considering six cohorts) reported on oral
HPV infections: eight in men and five in women (Table 6).
Incidence in men
The incidence of oral HPV infection was 5.7–6.1/100
person-years in HIV + ve men and 6.7/100 person-years
in HIV-ve men [23, 44]. In another study conducted in
university students, oral HPV incidence over 1 year was
12.3 % [45]. Finally, in the Finnish cohort, oral HPV in-
fection was reported in 14.3–69.2 % of male partners of
pregnant women 7 years after baseline. The variability in
results was due to the varying sampling timetable [30,
46]. In studies reporting type-specific incidence, HPV-16
was the most frequently identified type [44, 45, 47, 48].
Two studies reported age-specific incidence rates of
oral infections in men. In one study in university stu-
dents the age-specific incidence was higher in the 21–24
years age-group than in the 18–20 years age-group [45].
In HIV-ve men there was no increased risk of incident
HR-HPV oral infection across age groups (range 18–73
years) [44].
Incidence in women
The incidence of oral HPV infections in HIV-ve women
was 6.8–20.4/100 person-years versus 39.6/100 person-
years in HIV + ve women [15, 49]. In the Finnish cohort,
oral infections were present in approximately 10 % of
men and women after 24 months follow-up, and in
14.3 % of men and women after 7 years [30, 50]. Inci-
dence rates in women appeared to be similar or higher
than rates in men, depending on the study.
Clearance and persistence in men and women
Clearance rates of oral infections in men were reported
in two study cohorts (Table 6). In HIV + ve men, the
clearance rate of prevalent oral infections in MSM was
19.3/100 person-years, or 48.3 % after two-year follow-
up [23, 47]. Rates for HIV + ve MSW were 15.8/100
person-years and 34 %, respectively [23, 47]. The time-
to-clearance of oral HR-HPV in HIV-ve men was
6.9 months. Time-to-clearance of oral HPV-16 infection
was between 7.3 and 37.1 months in HIV-ve men, and
was higher (42.3–48.3 months) in HIV + ve men (Fig. 1).
In the Finnish cohort, approximately 5 % of oral HR-
HPV infections in 19 HR-HPV-positive men had cleared
by 24 months [50].
In US studies, clearance of any oral HPV in women was
60.6 % at 3 months [49], and clearance at 6 months was
20.0 % in HIV-ve women and 40.0 % in HIV + ve women
[15]. No oral HPV infections had cleared in women in the
Finnish cohort at 24 months, whereas clearance at 7 years
was 100 % [30, 50]. Among women with persistent
cervical HPV infection the time-to-clearance of oral HPV
infection was 50.0 months, versus 28.2 months in women
without cervical HPV infections (Fig. 1) [51].
Persistence of oral HPV infections was reported for three
cohorts (Table 3). In 662 healthy volunteers in Japan, four
had a prevalent infection and two had persistent infection
with the same HPV-type after 2.5 years [52]. The persist-
ence of prevalent HR-HPV infections in male and female
university students was 42 % after three months [49]..
Risk factors for non-cervical and oral HR-HPV infection
Penile and/or male genital infections with HR-HPV were
significantly associated with younger age in only one
study [19], although three articles reported no significant
association with age [17, 31, 53]. Other significant risk
factors were anal intercourse, HPV status of the partner,
number of partners (current or lifetime), and HIV infec-
tion [17, 19, 22, 26, 31, 53]. Being uncircumcised was
identified as a risk factor for penile HR-HPV infection in
one study in HIV-ve men [19], but not in another [28].
An increased likelihood of clearance of HR-HPV
penile infection was associated with an increased num-
ber of sex partners and circumcision (in HIV-ve men)
[19, 31]. One study reported increased clearance in men
with self-reported urethral discharge [19], but other
sexually-transmitted genital infections were not associ-
ated with clearance [19, 31].
Risk factors for anal HR-HPV infection in women were
younger age, condom use (possibly due to using the same
condom for vaginal and anal sex), higher lifetime number
of partners (≥6), and advanced HIV infection and smoking
(in HIV + ve women) [36, 37]. There was decreased likeli-
hood of clearance of anal HR-HPV infection in women
with a 2–10-pack-year smoking history [39].
No risk factors were significantly associated (multivari-
ate analyses) with anal HR-HPV infection in men.
Risk factors for persistence of oral HR-HPV were only
available from one study: a history of smoking was
significantly associated with longer persistence whereas
a history of genital warts was associated with shorter
persistence [46].
Discussion
The available data suggest a high incidence of non-
cervical HPV infections in men and women, with HPV-
16 most consistently ranking among the HR-HPV types
with the highest incidence rates and the lowest clearance
rates in all sites. Despite relatively few studies providing
data for cervical and other genital infections in compar-
able populations, there appears to be a general pattern
of both higher incidence and clearance of non-cervical
versus cervical genital infections. Around one-half of the
identified articles assessed HPV at male penile/other
genital sites. There was a wide variation in HPV inci-
dence reported at these sites, although the time-to-
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Table 6 Incidence and clearance of oral HPV infections
Author (ref) Population, age (years) Incidence (95 % CI) Clearance
Unit Any HPV HR 16 18 Infection type Unit of clearance Any HPV HR 16 18
Males
Edelstein [45] Male students,
median 20







- - - - - -
Kero [48] Male partners of
pregnant women,
19–46




- - - - - -
Kero [30]a Male partners of
pregnant women,
20–52
% at 7 years 14.3 %
(NTS)
(4.8–30.3)
- - - Prevalent % at 7 years 100 % (TS)
(64.4–100)
- - -
Kero [46]a Male partners of
pregnant women,
20–52
% at 7 years 69.2 % (TS)
(59.5–77.2)






Rintala [50] Male partners of
pregnant women,
20–52
% at 24 m - ~10 %
(NTS, first)
- - Prevalent % at 24 m - ~5 % (NTS) - -
Videla [23] HIV + ve MSM,
20- > 69













Darwich [47] HIV + ve MSM,
20- > 69
HIV + ve MSW,
20- > 69





























- - - - - -
Women
Pickard [49] Female students,
18–30
per 100py 6.8 (TS)
(3.7–9.8)








D’Souza [15] HIV-ve women
HIV + ve women










Kero [30] Pregnant women,
19–46
% at 7 years 14.3 % (NTS)
(5.4–28.5)
- - - Prevalent % at 7 years 100 % (TS)
(29.2–100)
- - -
Rintala [50] Pregnant women,
19–46
% at 24 m - ~10 %
(NTS, first)













Table 6 Incidence and clearance of oral HPV infections (Continued)
Men and women
Kurose [52] Male/female volunteers,
3–85





Abbreviations: MSM men who have sex with men, MSW men who have sex with women, py person-years, y years, m months, TS type-specific incidence defined as at least one positive test for any HPV type or HR-HPV
type not detected at baseline, NTS non-type-specific incidence defined as at least one positive test for any HPV type or HR-HPV type among those negative for any HPV DNA or any HR-HPV DNA at baseline
aStudy [30] considered a subset of men (46/131) included in [46]. Study [30] reported HPV status at baseline and at 7 years, whereas study [46] considered HPV status at baseline and all subsequent follow-up visits













clearance was comparable across all studies, with the ex-
ception of substantially longer time-to-clearance in HIV
+ ve men. HIV status, circumcision, number of sex part-
ners and HPV status of the partner significantly influenced
HR-HPV incidence, clearance and persistence rates at
male anogenital sites in some, but not all studies. Some of
these risk factors are the same as those identified for
cervical HPV infection, for which the number of sex part-
ners is the most important one [54].
Unlike cervical intraepithelial neoplasia, anal-
intraepithelial neoplasia infrequently undergoes malig-
nant transformation in immunocompetent individuals,
but the risk of malignant transformation is much greater
in HIV + ve individuals [55]. Corresponding with the
higher incidence of anal cancer in MSM and HIV + ve men
compared to the general population, we also found consist-
ently higher incidences of anal HPV infection in these
groups compared to MSW and HIV-ve men, respectively.
There was a lack of similar comparison data for these risk
groups for clearance. The primary exception was Nyitray
et al. [35], which indicated potentially lower clearance rates
for MSM versus MSW, but multivariate analyses directly
comparing the two groups within the same model were not
conducted.
The Hawaiian studies by Goodman et al. showed an
incidence of anal HPV infection that was three-times
higher than cervical HPV infection [36, 39, 41], although a
recent review concluded that the prevalence of anal and
cervical infections are similar in women, and that cervical
HPV infection is a risk factor for anal HPV infection [56].
As prevalence is determined by the incidence rate multi-
plied by the average duration of infection, the similar
prevalence between anal and cervical infections could be
due the higher incidence of anal infections being offset by
simultaneously higher clearance. The Hawaiian cohorts
provided indication of higher clearance of anal infections,
but despite this study having one of the largest, most care-
fully followed cohorts, there were limited samples sizes to
assess clearance rates, especially for individual types. This
was in part due to the fact that the analyses of clearance
focused on infections that were acquired during the
course of the study.
The incidence of oral HPV infection was within the same
range in men and women, although the prevalence of oral
HPV infection has been reported to be higher in men [57].
Our data were too limited to conclude whether there were
differences in persistence or clearance rates between men
and women. It is thought that the oncogenicity of HPV is
similar in oral and cervical cancers, although numerous
gaps remain in understanding the risk factors that influence
progression from oral infection to oral neoplasia [57].
The factors that influence oncogenesis at non-cervical
sites are not well understood, and appear to differ by site
and between populations (including men versus women,
immunosuppressed versus immunocompetent, circum-
cised versus uncircumcised) [57, 58]. Although the inci-
dence of HPV infection at non-cervical sites appears to
be high, the increased capacity for clearance of HPV ob-
served may contribute to the lower occurrence of these
types of cancers. Overall, data describing the natural his-
tory of non-cervical cancers are lacking.
A potential limitation of our study is the non-inclusion
of articles in which vaginal swabs were self-collected. The
single study that we identified using physician-collected
vaginal swabs may not be representative for this site as it
was limited to university students. However, it was one of
the highest quality studies, following more than 400
women aged 18–20 years old every 4 months for 10 years
and prospectively collecting sexual behavior data. The
studies on cervical infections were selected from specific
non-systematic searches aimed to identify comparable
populations with which to compare to non-cervical infec-
tions. Thus, the results may not be applicable beyond the
study setting. Most studies were not properly designed for
risk factor analysis and should be interpreted cautiously.
The studies we identified were substantially different in
terms of their design, including follow-up times and sam-
pling intervals which ranged from several months to 7 years,
as well as the number of types and methods used for HPV
genotyping. Although it is difficult to apply a standard grad-
ing to these studies, the highest quality studies tended to be
those that followed cohorts of at least 200 subjects and
conducted multiple follow-up visits ≤6 months apart for at
least one year. At least one such study provided data for
each of the sampling sites: penile [17–19, 22, 24, 53], male
genital [25, 26, 28, 31, 53, 59], anal [34, 36, 38, 39],
vulvovaginal [43], oral [44].
The available published data are limited by the lack of
age-specific estimates, and information on clearance/per-
sistence of infection was frequently based on very small
sample sizes, resulting in imprecise estimates. Few studies
provided incidence or clearance data on oral or anal HPV
infections in women versus men, and the relative burden
of these infections in each sex is not clear. Specific esti-
mates of incidence and clearance of HPV-16, which is in-
volved in the majority of non-cervical cancers, and HPV-
18 which may also be important in some sites, as well as
estimation of clearance rates at 6 and 12 months, could
inform on potentially important endpoints for clinical tri-
als of vaccine efficacy. Finally, because just a few countries
contributed data to this review and given the important
differences in study designs, outcomes and populations, it
is important to note the limited generalizability of these
results to other populations.
Conclusions
Cases of cervical cancer are projected to increase, empha-
sising the importance of ongoing efforts to provide access
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of effective HPV vaccines to all [1, 60]. As yet, the implica-
tions of HPV vaccination for prevention of non-cervical
cancers have not been fully explored [58]. Some countries
have recommended HPV vaccination for young males on
the basis that vaccination will prevent HPV-associated
cancers in men, as well as theoretical benefits in prevent-
ing transmission of HPV to women [61, 62]. Programs
targeting prevention of cervical HPV infection could have
additional benefits on the non-cervical disease burden.
This review suggests that there are parallels between the
epidemiology of cervical and non-cervical HPV infections
in terms of the incidence and distribution of HPV types,
and of risk factors for HPV infection. However, these
parallels may not be directly applicable to disease at non-
cervical sites. More detailed and extensive studies could
provide useful information for estimating vaccine impact,
the wider cost-benefit of HPV vaccination, and for guiding
vaccination policy.
Additional files
Additional file 1: Search strings; Article screening; Data extraction;
Identification of papers on cervical HPV infection in same/similar study
populations; Quality control. (DOCX 139 kb)
Additional file 2: Table S1. Summary of HPV testing conducted in 38
articles included in the review. (XLSX 38 kb)
Abbreviations
2+ neg, 2 or more negative test results required to define an infection as
having cleared; CI, confidence intervals; HIV, human immunodeficiency virus;
HPV, human papilloma virus; HR, High risk; LR, low risk; MSM, men who have
sex with men; MSW, men who have sex with women; NTS, non-type specific;
TS, type specific
Acknowledgements
The authors thank Attila Mihalyi (Global Medical Affairs, Vaccines Value and
Health Science at GSK Vaccines) for critically reviewing the manuscript, and
Joanne Wolter (independent medical writer, Brisbane, Australia on behalf of
GSK Vaccines) who provided writing services and contributed to data
extraction and checking. Editing and publication co-ordinating services
were provided by Veronique Delpire and Mandy Payne (Words and Science,
Brussels, Belgium on behalf of GSK Vaccines). All costs related to the
development of this manuscript were met by GlaxoSmithKline Biologicals SA.
Funding
GlaxoSmithKline Biologicals SA was the funding source and was involved in
design and conduct of the study; management, analysis, and interpretation
of the data; preparation, review and approval of the manuscript and decision
to submit the manuscript for publication. Pallas was involved in the design
of the study, conducted the literature review, and review and approval of
manuscript. GlaxoSmithKline Biologicals SA funded all costs associated with
the development and the publishing of the present manuscript. The
corresponding author had full access to the data and was responsible for
submission of the publication.
Availability of data and materials
All data used in this study originates from published studies and are
referenced accordingly in this manuscript.
Authors’ contribution
ST conceived the review and ST, EB, MB and XC participated in the design.
EB and MB collected and assembled the data, and performed the analysis. ST
and XC supervised the analysis. All authors interpreted the data, and




ST is an employee of, and owns share options in, the GSK group of companies.
EB and MB are employees of Pallas health research and consultancy BV, a
commercial entity that has received grants and carried out part of the
submitted work as a supplier to GSK Vaccines. Pallas has been a supplier of
literature reviews and other epidemiological services to GSK Vaccines in the
past 36 months. These works cover a variety of vaccines that are in
development or on the market.
XC reports having received institutional research and/or educational grants
from Merck, Sanofi Pasteur MSD, GSK Vaccines, and Genticel, and occasional




Ethics approval and consent to participate
Not applicable.
Author details
1GSK Vaccines, 20, Avenue Fleming, Parc de la Noire Epine, B-1300 Wavre,
Belgium. 2Pallas Health Research and Consultancy BV, Rotterdam, The
Netherlands. 3Cancer Epidemiology Research Program, Catalan Institute of
Oncology (ICO), IDIBELL, L’Hospitalet de Llobregat, Catalonia, Spain. 4CIBER
Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Received: 18 September 2015 Accepted: 7 June 2016
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11 [Internet]. Lyon, France: International Agency for
Research on Cancer. Available from http://globocan.iarc.fr.
2. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.
Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
3. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S.
Prevalence and type distribution of human papillomavirus in carcinoma
and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.
Int J Cancer. 2009;124:1626–36. doi:10.1002/ijc.24116.
4. HPV Information Centre. Data Query. 2014. http://www.hpvcentre.net/
dataquery.php (accessed 6 Mar 2015).
5. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma
related to human papillomavirus. BMJ. 2010;340:c1439.
6. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global
burden of cancers attributable to infections in 2008: a review and synthetic
analysis. Lancet Oncol. 2012;13:607–15. doi:10.1016/S1470-2045(12)70137-7.
7. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al.
Reduced prevalence of oral human papillomavirus (HPV) 4 years after
bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS
ONE. 2013;8:e68329. doi:10.1371/journal.pone.0068329.
8. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C,
et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease
in males. N Engl J Med. 2011;364:401–11. doi:10.1056/NEJMoa0909537.
9. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al.
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N
Engl J Med. 2011;365:1576–85. doi:10.1056/NEJMoa1010971.
10. Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn L-J, Schiffman M, Struijk L,
et al. Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who
Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa
Rica Vaccine Trial. J Infect Dis. 2014;210:1890–9. doi:10.1093/infdis/jiu357.
11. Muñoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler
CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all
HPV-associated genital diseases in young women. J Natl Cancer Inst.
2010;102:325–39. doi:10.1093/jnci/djp534.
Taylor et al. BMC Infectious Diseases  (2016) 16:293 Page 19 of 21
12. Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al.
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection
among young women: a nested analysis within the Costa Rica Vaccine Trial.
Lancet Oncol. 2011;12:862–70. doi:10.1016/S1470-2045(11)70213-3.
13. McCormack PL. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
Recombinant Vaccine (Gardasil(®)): A Review of Its Use in the Prevention of
Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital
Warts. Drugs. 2014;74:1253–83. doi:10.1007/s40265-014-0255-z.
14. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human
papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38.
doi:10.1016/j.vaccine.2012.04.108.
15. D’Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL, et al.
Six-month natural history of oral versus cervical human papillomavirus
infection. Int J Cancer. 2007;121:143–50. doi:10.1002/ijc.22667.
16. Serwadda D, Wawer MJ, Makumbi F, Kong X, Kigozi G, Gravitt P, et al.
Circumcision of HIV-infected men: effects on high-risk human
papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis.
2010;201:1463–9. doi:10.1086/652185.
17. Backes DM, Snijders PJF, Hudgens MG, Bailey RC, Bogaarts M, Agot K, et al.
Sexual behaviour and less frequent bathing are associated with higher
human papillomavirus incidence in a cohort study of uncircumcised Kenyan
men. Sex Transm Infect. 2013;89:148–55. doi:10.1136/sextrans-2012-050532.
18. Gray RH, Serwadda D, Kong X, Makumbi F, Kigozi G, Gravitt PE, et al. Male
circumcision decreases acquisition and increases clearance of high-risk
human papillomavirus in HIV-negative men: a randomized trial in Rakai,
Uganda. J Infect Dis. 2010;201:1455–62. doi:10.1086/652184.
19. Tobian AAR, Kigozi G, Gravitt PE, Xiao C, Serwadda D, Eaton KP, et al.
Human papillomavirus incidence and clearance among HIV-positive and
HIV-negative men in sub-Saharan Africa. AIDS. 2012;26:1555–65. doi:10.1097/
QAD.0b013e328353b83c.
20. Darwich L, Cañadas M-P, Videla S, Coll J, Molina-López RA, Sirera G, et al.
Prevalence, clearance, and incidence of human papillomavirus type-specific
infection at the anal and penile site of HIV-infected men. Sex Transm Dis.
2013;40:611–8. doi:10.1097/01.OLQ.0000430798.61475.08.
21. Wikström A, Popescu C, Forslund O. Asymptomatic penile HPV infection: a
prospective study. Int J STD AIDS. 2000;11:80–4.
22. Mbulawa ZZA, Marais DJ, Johnson LF, Coetzee D, Williamson A-L. Impact of
human immunodeficiency virus on the natural history of human
papillomavirus genital infection in South African men and women. J Infect
Dis. 2012;206:15–27. doi:10.1093/infdis/jis299.
23. Videla S, Darwich L, Cañadas M-P, Coll J, Piñol M, García-Cuyás F, et al.
Natural history of human papillomavirus infections involving anal, penile,
and oral sites among HIV-positive men. Sex Transm Dis. 2013;40:3–10. doi:
10.1097/OLQ.0b013e31827e87bd.
24. Grabowski MK, Gray RH, Serwadda D, Kigozi G, Gravitt PE, Nalugoda F, et al.
High-risk human papillomavirus viral load and persistence among
heterosexual HIV-negative and HIV-positive men. Sex Transm Infect.
2014;90:337–43. doi:10.1136/sextrans-2013-051230.
25. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee J-H, et al.
Age-specific prevalence, incidence, and duration of human papillomavirus
infections in a cohort of 290 US men. J Infect Dis. 2008;198:827–35.
doi:10.1086/591095.
26. Morales R, Parada R, Giuliano AR, Cruz A, Castellsagué X, Salmerón J, et al.
HPV in female partners increases risk of incident HPV infection acquisition in
heterosexual men in rural central Mexico. Cancer Epidemiol Biomarkers
Prev. 2012;21:1956–65. doi:10.1158/1055-9965.EPI-12-0470.
27. Lajous M, Mueller N, Cruz-Valdéz A, Aguilar LV, Franceschi S, Hernández-
Avila M, et al. Determinants of prevalence, acquisition, and persistence of
human papillomavirus in healthy Mexican military men. Cancer Epidemiol
Biomarkers Prev. 2005;14:1710–6. doi:10.1158/1055-9965.EPI-04-0926.
28. Albero G, Castellsagué X, Lin H-Y, Fulp W, Villa LL, Lazcano-Ponce E, et al.
Male circumcision and the incidence and clearance of genital human
papillomavirus (HPV) infection in men: the HPV Infection in men (HIM)
cohort study. BMC Infect Dis. 2014;14:75. doi:10.1186/1471-2334-14-75.
29. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi L-F, et al. Genital
human papillomavirus infection in men: incidence and risk factors in a cohort
of university students. J Infect Dis. 2007;196:1128–36. doi:10.1086/521192.
30. Kero KM, Rautava J, Syrjänen K, Kortekangas-Savolainen O, Grenman S,
Syrjänen S. Stable marital relationship protects men from oral and genital
HPV infections. Eur J Clin Microbiol Infect Dis. 2014;33:1211–21. doi:10.1007/
s10096-014-2061-7.
31. Lu B, Wu Y, Nielson CM, Flores R, Abrahamsen M, Papenfuss M, et al. Factors
associated with acquisition and clearance of human papillomavirus
infection in a cohort of US men: a prospective study. J Infect Dis.
2009;199:362–71. doi:10.1086/596050.
32. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al.
Incidence, prevalence, and clearance of type-specific human papillomavirus
infections: The Young Women’s Health Study. J Infect Dis. 2002;186:462–9.
doi:10.1086/341782.
33. Glick SN, Feng Q, Popov V, Koutsky LA, Golden MR. High rates of incident and
prevalent anal human papillomavirus infection among young men who have
sex with men. J Infect Dis. 2014;209:369–76. doi:10.1093/infdis/jit441.
34. Hernandez AL, Efird JT, Holly EA, Berry JM, Jay N, Palefsky JM. Incidence of
and risk factors for type-specific anal human papillomavirus infection
among HIV-positive MSM. AIDS. 2014;28:1341–9. doi:10.1097/QAD.
0000000000000254.
35. Nyitray AG, da Silva RJ C, Baggio ML, D’elle S, Abrahamsen M, Papenfuss M,
et al. Six-month incidence, persistence, and factors associated with
persistence of anal human papillomavirus in men: the HPV in men study.
J Infect Dis. 2011;204:1711–22. doi:10.1093/infdis/jir637.
36. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Ning L, et al.
Acquisition of anal human papillomavirus (HPV) infection in women: the
Hawaii HPV Cohort study. J Infect Dis. 2008;197:957–66. doi:10.1086/529207.
37. Mullins TLK, Wilson CM, Rudy BJ, Sucharew H, Kahn JA. Incident anal human
papillomavirus and human papillomavirus-related sequelae in HIV-infected
versus HIV-uninfected adolescents in the United States. Sex Transm Dis.
2013;40:715–20. doi:10.1097/01.olq.0000431049.74390.b7.
38. de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, et al.
Prevalence, clearance, and incidence of anal human papillomavirus infection
in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199:965–73.
doi:10.1086/597207.
39. Shvetsov YB, Hernandez BY, McDuffie K, Wilkens LR, Zhu X, Ning L, et al.
Duration and clearance of anal human papillomavirus (HPV) infection
among women: the Hawaii HPV cohort study. Clin Infect Dis.
2009;48:536–46. doi:10.1086/596758.
40. Moscicki A-B, Ma Y, Farhat S, Jay J, Hanson E, Benningfield S, et al. Natural
history of anal human papillomavirus infection in heterosexual women and
risks associated with persistence. Clin Infect Dis. 2014;58:804–11.
doi:10.1093/cid/cit947.
41. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ,
et al. Prevalence, acquisition, and clearance of cervical human
papillomavirus infection among women with normal cytology: Hawaii
Human Papillomavirus Cohort Study. Cancer Res. 2008;68:8813–24.
doi:10.1158/0008-5472.CAN-08-1380.
42. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The
natural history of human papillomavirus infection as measured by repeated
DNA testing in adolescent and young women. J Pediatr. 1998;132:277–84.
43. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital
human papillomavirus infection: incidence and risk factors in a cohort of
female university students. Am J Epidemiol. 2003;157:218–26.
44. Kreimer AR, Pierce Campbell CM, Lin H-Y, Fulp W, Papenfuss MR,
Abrahamsen M, et al. Incidence and clearance of oral human papillomavirus
infection in men: the HIM cohort study. Lancet. 2013;382:877–87.
doi:10.1016/S0140-6736(13)60809-0.
45. Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al.
Rates and determinants of oral human papillomavirus infection in young
men. Sex Transm Dis. 2012;39:860–7. doi:10.1097/OLQ.0b013e318269d098.
46. Kero K, Rautava J, Syrjänen K, Willberg J, Grenman S, Syrjänen S. Smoking
increases oral HPV persistence among men: 7-year follow-up study. Eur J
Clin Microbiol Infect Dis. 2014;33:123–33. doi:10.1007/s10096-013-1938-1.
47. Darwich L, Cañadas MP, Videla S, Coll J, Molina-López RA, Cobarsi P, et al. Oral
human papillomavirus type-specific infection in HIV-infected men: a prospective
cohort study among men who have sex with men and heterosexual men. Clin
Microbiol Infect. 2014;20:O585–9. doi:10.1111/1469-0691.12523.
48. Kero K, Rautava J, Syrjänen K, Grenman S, Syrjänen S. Oral mucosa as a
reservoir of human papillomavirus: point prevalence, genotype distribution,
and incident infections among males in a 7-year prospective study. Eur
Urol. 2012;62:1063–70. doi:10.1016/j.eururo.2012.06.045.
49. Pickard RKL, Xiao W, Broutian TR, He X, Gillison ML. The prevalence and
incidence of oral human papillomavirus infection among young men and
women, aged 18–30 years. Sex Transm Dis. 2012;39:559–66. doi:10.1097/
OLQ.0b013e31824f1c65.
Taylor et al. BMC Infectious Diseases  (2016) 16:293 Page 20 of 21
50. Rintala M, Grénman S, Puranen M, Syrjänen S. Natural history of oral
papillomavirus infections in spouses: a prospective Finnish HPV Family
Study. J Clin Virol. 2006;35:89–94. doi:10.1016/j.jcv.2005.05.012.
51. Louvanto K, Rautava J, Syrjänen K, Grénman S, Syrjänen S. The clearance of
oral high-risk human papillomavirus infection is impaired by long-term
persistence of cervical human papillomavirus infection. Clin Microbiol Infect.
2014;20:1167–72. doi:10.1111/1469-0691.12700.
52. Kurose K, Terai M, Soedarsono N, Rabello D, Nakajima Y, Burk RD, et al. Low
prevalence of HPV infection and its natural history in normal oral mucosa
among volunteers on Miyako Island, Japan. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2004;98:91–6. doi:10.1016/S1079210404000265.
53. Giuliano AR, Lee J-H, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al.
Incidence and clearance of genital human papillomavirus infection in men
(HIM): a cohort study. Lancet. 2011;377:932–40. doi:10.1016/S0140-
6736(10)62342-2.
54. Chelimo C, Wouldes TA, Cameron LD, Elwood JM. Risk factors for and
prevention of human papillomaviruses (HPV), genital warts and cervical
cancer. J Infect. 2013;66:207–17. doi:10.1016/j.jinf.2012.10.024.
55. Scholefield JH, Castle MT, Watson NFS. Malignant transformation of
high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92:1133–6.
doi:10.1002/bjs.4994.
56. Stier EA, Sebring MC, Mendez AE, Ba FS, Trimble DD, Chiao EY. Prevalence
of anal human papillomavirus infection and anal HPV-related disorders in
women: a systematic review. Am J Obstet Gynecol. 2015;213:278–309.
doi:10.1016/j.ajog.2015.03.034.
57. Blitzer GC, Smith MA, Harris SL, Kimple RJ. Review of the clinical and
biologic aspects of human papillomavirus-positive squamous cell
carcinomas of the head and neck. Int J Radiat Oncol Biol Phys.
2014;88:761–70. doi:10.1016/j.ijrobp.2013.08.029.
58. Harper DM, Vierthaler SL. Who should be targeted for vaccination against anal
cancer? Lancet Oncol. 2011;12:828–9. doi:10.1016/S1470-2045(11)70237-6.
59. Hernandez BY, Shvetsov YB, Goodman MT, Wilkens LR, Thompson P, Zhu X,
et al. Reduced clearance of penile human papillomavirus infection in
uncircumcised men. J Infect Dis. 2010;201:1340–3. doi:10.1086/651607.
60. Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, et al.
Public health value of universal HPV vaccination. Crit Rev Oncol Hematol.
2016;97:157–67. doi:10.1016/j.critrevonc.2015.07.015.
61. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al.
Human papillomavirus vaccination: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Recomm Rep.
2014;63:1–30.
62. Australian Government Department of Health and Ageing, National Health and
Medical Research Council. The Australian Immunisation Handbook. 10th ed. 2015.
63. Kjaer SK, Munk C, Winther JF, Jørgensen HO, Meijer CJLM, van den Brule AJC.
Acquisition and persistence of human papillomavirus infection in younger
men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol
Biomarkers Prev. 2005;14:1528–33. doi:10.1158/1055-9965.EPI-04-0754.
64. Videla S, Darwich L, Cañadas MP, Paredes R, Tarrats A, Castella E, et al.
Epidemiological data of different human papillomavirus genotypes in
cervical specimens of HIV-1-infected women without history of cervical
pathology. J Acquir Immune Defic Syndr. 2009;50:168–75. doi:10.1097/QAI.
0b013e3181938e63.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Taylor et al. BMC Infectious Diseases  (2016) 16:293 Page 21 of 21
